TriState urologic Services PSC Inc., dba The Urology Group

Cincinnati, Ohio 45212

1 studies enrolling now · 13 studies all time

What they study most

Bladder Carcinoma in Situ (CIS), Cancer of the Prostate, Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Cystitis, Interstitial, Hormone Sensitive Prostate Cancer, Metastatic Castrate-sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC), Overactive Bladder, Preneoplastic Conditions, Prostate Cancer, Prostatic Intraepithelial Neoplasia, Prostatic Neoplasms

Studies at this site

• This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve. — Recruiting now
• A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC — Running, not enrolling
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia) — Completed
• A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome — Stopped early
• An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis — Completed
• An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis — Completed
• Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T — Stopped early
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed
• OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder — Completed
• Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result — Completed